회사 소개
- 법인명: Regenix drugs Ltd
- 등록 국가: India
- 주소: B-26, Phase -II, Zone B ,MEPZ -SEZ, Tambaram, , Tamilnadu
- 직원 수: 50 - 99
- 설립 연도: 2007
설명:
Regenix is a biosimilar injection formulation and fill-finish manufacturing facility located in Chennai, India. A WHO-GMP-accredited, state-of-the-art facility spanning 30,000 square feet, designed to the latest GMP regulatory standards to fill sterile products in vials, pre-filled syringes and cartridges, the company's current CTD-format dossier product list includes human insulin injection (R, 30/70 and NPH), Insulin Glargine, Liraglutide and Enoxaparin Sodium injections.
사업 활동
완제 의약품
제조업체
바이오의약품
제조업체
ATC 분류체계 (해부치료화학분류)
제조업체
판매 시장
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Northern Europe: Iceland, Norway, United Kingdom
- Southern Europe: Albania, Andorra, Bosnia and Herzegovina, North Macedonia, Montenegro, Serbia, Vatican City
주요 제품/서비스
- 완제 의약품: Similin® 30(insulin human 30 injection)
- 바이오의약품: Biosimilar injectables
- ATC 분류체계 (해부치료화학분류): Insulin Glargine injection 100IU/Ml, Liraglutide injection 6mg/ml (rDNA origin), Insulin Injection soluble (Regular), Biphasic isophane insulin injection (30/70), Isophane Insulin Injection (rDNA origin)
당사 제품 & 서비스
인증
GMP
ISO
증거
CPHI Milan 2026
10/2026 – 10/2026
CPHI Milan 2026
평점
(0)
(0)
(0)
(0)
(0)
댓글
필터:
정렬:
댓글이 없습니다.
평가 & 댓글 남기기